Answers are grounded in this paper and cite their sources.
Background: Inflammatory plasma proteins have been associated with poorer clinical outcomes in melanoma patients treated with immune checkpoint inhibitors (ICIs). Furthermore, the plasma levels of thymidine kinase activity (TKa), an indicator of proliferation, have also been associated with adverse outcomes in several cancers. The aim of this study was to explore the relationship between TKa, systemic inflammation and survival in ICI-treated melanoma patients. Materials and methods: Fifty-eight patients with unresectable metastatic melanoma who received anti-programmed cell death protein 1 monotherapy were included in the study. Pretreatment plasma samples were analyzed for TKa levels (DiviTum® TKa assay; Biovica) and inflammatory proteins using the Olink® Target 96 Inflammation panel, and these biomarkers were correlated with patient survival. Conclusion: This multi-biomarker panel was independently associated with poor OS in ICI-treated melanoma patients. This finding suggests a prognostic value of the panel, indicating its potential relevance for stratifying patients by risk, although further validation in larger cohorts is warranted.
No takes yet. Share an insight, caveat, or question.
Brage et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: